HK Stock Market Move | HBM HOLDINGS-B (02142) rose more than 6% and further deepened cooperation with AstraZeneca. The AI wet and dry laboratory platform is about to be officially put into use.

HBM HOLDINGS-B (02142) rose more than 6%, as of the time of publication, with a 6.35% increase, closing at HKD 13.23 with a trading volume of HKD 9.9394 million. On the news front, according to the official WeChat account of Heng Bo Pharmaceutical, on October 25, the Heng Bo Pharmaceutical-AstraZeneca Innovation Laboratory was officially launched in Beijing, marking a further deepening of cooperation between the two parties. The full-process research and development of new generation antibody drugs from discovery to optimization has entered the "fast track". So far, the two parties have formed a diversified cooperation model of "research and development cooperation + equity investment + establishment of Beijing Innovation Center", injecting new energy into innovative drug research and development. It is reported that in March of this year, Heng Bo Pharmaceutical and AstraZeneca reached a global strategic cooperation to jointly research and develop a new generation of multi-specific antibody therapies for immunological diseases, tumors, and other diseases, and promote cutting-edge scientific research at the BJ PROPERTIES innovation laboratory. After several months of preparation, the innovation laboratory is fully operational, the Heng Bo Pharmaceutical antibody drug innovation development platform and AI wet and dry laboratory platforms have been built and will soon be put into official use, helping to drive the research and development of new generation therapeutic antibodies in multiple fields.